Oragenics: Starting Public
This article was originally published in Start Up
Oragenics opted for an IPO when VC backing failed to materialize, landing enough cash to advance its varied programs. Managing a public start-up in the Sarbanes-Oxley era has been a challenge for the Florida biotech, whose lead product is a genetically modified bacteria aimed at eliminating dental cavities.
You may also be interested in...
In assessing the sixteen biotechs making their public debuts over the past six months, investors clearly favor companies specializing in development, not discovery. What's more, investors especially prefer those development firms with late-stage products, lots of cash, and possibly even a sizable out-licensing deal.
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)